Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS.

Ther Clin Risk Manag. 2016 Jun 7;12:931-40. doi: 10.2147/TCRM.S86330. eCollection 2016. Review.

2.

Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.

Leuthner KD, Yuen A, Mao Y, Rahbar A.

Expert Rev Anti Infect Ther. 2015 Feb;13(2):149-59. doi: 10.1586/14787210.2015.995633. Review.

PMID:
25578881
3.

Antimicrobial stewardship and Clostridium difficile-associated diarrhea.

Piacenti FJ, Leuthner KD.

J Pharm Pract. 2013 Oct;26(5):506-13. doi: 10.1177/0897190013499528. Epub 2013 Aug 14. Review.

PMID:
23946208
4.

Antimicrobial stewardship programs.

Leuthner KD, Doern GV.

J Clin Microbiol. 2013 Dec;51(12):3916-20. doi: 10.1128/JCM.01751-13. Epub 2013 Aug 7. Review.

5.

In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

Leuthner KD, Vidaillac C, Cheung CM, Rybak MJ.

Antimicrob Agents Chemother. 2010 Sep;54(9):3799-803. doi: 10.1128/AAC.00452-10. Epub 2010 Jun 28.

8.

Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae.

Leuthner KD, Cheung CM, Rybak MJ.

Antimicrob Agents Chemother. 2006 Feb;50(2):813-6.

Supplemental Content

Loading ...
Support Center